Enhanced CD33 CAR-NK cells secreting anti-CD73scFv overcome adenosine-mediated immunosuppression and improve anti-AML efficacy
Enhanced immune cells engineered to fight leukemia overcome the tumor's defense shields, improving effectiveness in hard-to-treat cases.
This PubMed-indexed observational or laboratory study examines Enhanced CD33 CAR-NK cells secreting anti-CD73scFv overcome adenosine-mediated immunosuppression and improve anti-AML efficacy. The available abstract reports Acute myeloid leukemia (AML) is an aggressive hematologic malignancy with dismal outcomes, especially in relapsed/refractory settings Chimeric antigen receptor natural killer (CAR-NK) cell therapy holds promise but is constrained by the immunosuppressive tumor microenvironment (TME), where adenosine-mediated.
What the study was
- Study design
- Observational or laboratory study
- Population
- Human participants
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Journal for immunotherapy of cancer
Why it surfaced
Conservative rapid triage: observational or laboratory study, mixed evidence, and direct relevance to Hematologic malignancies.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.